KOREA

Anthony Albanese puts interventionist industry policy at the centre of his budget agenda

Retrieved on: 
Wednesday, April 10, 2024

Anthony Albanese will outline on Thursday a strongly interventionist role for government to make Australia competitive in a world requiring us to “break with old orthodoxies”.

Key Points: 
  • Anthony Albanese will outline on Thursday a strongly interventionist role for government to make Australia competitive in a world requiring us to “break with old orthodoxies”.
  • In a major pre-budget address that puts industry policy at the heart of this agenda, the Prime Minister will declare his government “will not be an observer or a spectator – we will be a participant, a partner, an investor and enabler”.
  • To underpin the case for the government’s direction, Albanese highlights comparable countries that are investing in their industrial base, manufacturing capability and economic sovereignty.

‘Not old-fashioned protectionism’

  • Australia continued to champion global markets, but “equally, we must recognise that the partners we seek are moving to the beat of a new economic reality”.
  • “All these countries are investing in their industrial base, their manufacturing capability and their economic sovereignty.
  • And – critically – none of this is merely being left to market forces or trusted to the invisible hand.
  • "The heavy lifting of economic transition and industrial transformation is not being done by individuals, companies or communities on their own.
  • "It is being facilitated, enabled and empowered by national Governments from every point on the political spectrum.
  • Ramping up a rhetoric of urgency, Albanese says: “We need to be clear-eyed about the economic realities of this decade.


Michelle Grattan does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

EQS-News: Australian Patent Update

Retrieved on: 
Wednesday, April 10, 2024

EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.

Key Points: 
  • EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.
  • For full details refer:
    EcoGraf is considering its position in relation to the matter, specifically whether or not it intends to file amendments to overcome the deficiencies identified by the delegate in the Company’s Australian patent application and/or whether to exercise its right of appeal to the Federal Court.
  • The US Patent and Trademark Office has confirmed that the Company’s patent application, filed on 1 November 2022, entitled “Method of Producing Purified Graphite” was granted on 18 July 2023 as US Patent 11,702342 (refer ASX announcement US Patent Granted 19 July 2023).
  • The Company’s EcoGraf HFfree™ Australian Product Qualification Facility is being developed with the support of a $2.9m grant provided by the Australian Government under the Critical Minerals Development Program, with commissioning scheduled to commence next month.

CJ Biomaterials Names Harry Jang as New Chief Executive Officer

Retrieved on: 
Tuesday, March 19, 2024

Jang is a 29-year veteran of CJ CheilJedang, holding positions of leadership in countries around the world

Key Points: 
  • Jang is a 29-year veteran of CJ CheilJedang, holding positions of leadership in countries around the world
    Woburn, Massachusetts--(Newsfile Corp. - March 19, 2024) - CJ Biomaterials, Inc, a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, has named Harry Jang as its new Chief Executive Officer.
  • As the head of CJ Biomaterials, Jang will oversee the company's strategic direction, drive innovation in sustainable materials, and spearhead efforts to expand market presence and partnerships in the global bioplastics industry.
  • Jang joined CJ CheilJedang in 1995 and has taken over roles of increasing responsibility at CJ businesses around the world, working in Korea, Brazil, Vietnam, Germany, and most recently, the United States.
  • During his tenure, Jang helped CJ BIO America to grow its business, including an expansion of operations at its Ft.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Retrieved on: 
Tuesday, April 9, 2024

PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).

Key Points: 
  • Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
  • The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
  • The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
  • “We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

Retrieved on: 
Tuesday, April 9, 2024

The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.

Key Points: 
  • The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.
  • Therefore, the future course of the A6 strain as a BOTULINUM TOXIN provides a new opportunity in the botulinum field.
  • The company aims to capture the botulinum toxin market based on maximized utilization of its distribution network and experience.
  • "We will enhance the global market, especially the U.S., with novel botulinum toxin products," said Choi Yong-hoon, the CEO of WizMedi Bio.

Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report

Retrieved on: 
Monday, April 8, 2024

The 5th edition explores some IRA implications on biosimilars along with latest price trends, biosimilars market share

Key Points: 
  • The 5th edition explores some IRA implications on biosimilars along with latest price trends, biosimilars market share
    INCHEON, Korea, April 08, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its Second Quarter 2024 Biosimilar Market Report , which includes the latest Average Sales Price (ASP) information of all biosimilars and reference products available in the US market.
  • This fifth-edition of the Samsung Bioepis Quarterly Biosimilar Market Report delves into some implications of the Inflation Reduction Act (IRA) with respect to biosimilars, as well as the biosimilars market share and price trends.
  • “Over the past year, we have strived to provide the US market with the latest biosimilar insights through our report, and we are grateful for the positive reception from our readers,” said Thomas Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis.
  • As of February 2024, adalimumab biosimilar market share has reached 4%, increasing 2% compared to the previous quarter.

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

Retrieved on: 
Friday, April 5, 2024

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab).

Key Points: 
  • INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab).
  • The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer.
  • “We are thrilled to announce the initiation of Phase 3 clinical trial for SB27, after our successful Phase 1 clinical trial initiation in February 2024,” said Ilsun Hong, Vice President, Product Evaluation Team Leader of Samsung Bioepis.
  • “Based on our extensive clinical trial experience accumulated over the years, we will work closely with study investigators to ensure successful completion of the clinical trials for SB27.”

Golden State Wealth Management proudly welcomes Kathleen Stephens, Founder of Solaris Wealth Management, to its team

Retrieved on: 
Thursday, April 4, 2024

SOUTH COAST METRO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Golden State Wealth Management (“Golden State”) announced today the addition of Kathleen Stephens, who operates under the DBA, Solaris Wealth Management (“Solaris Wealth”) located in Poway, California.

Key Points: 
  • SOUTH COAST METRO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Golden State Wealth Management (“Golden State”) announced today the addition of Kathleen Stephens, who operates under the DBA, Solaris Wealth Management (“Solaris Wealth”) located in Poway, California.
  • She boasts a rich background shaped by her family's immigration journey from Seoul, Korea to Hawaii in the 1970s.
  • Because her parents did not speak any English, Kathleen was responsible for the family finances at an early age.
  • We couldn't be more delighted to have Kathleen as a part of our team," says Daniel R. Catone, Founder and CEO of Golden State Wealth Management.

Gov. Holcomb, IEDC announce generational multi-billion-dollar investment to make Indiana leader in semiconductor packaging

Retrieved on: 
Wednesday, April 3, 2024

The facility will also develop future generations of chips and house an advanced packaging R&D line.

Key Points: 
  • The facility will also develop future generations of chips and house an advanced packaging R&D line.
  • “We are excited to build a state-of-the-art advanced packaging facility in Indiana,” said SK hynix CEO Kwak Noh-Jung.
  • “We believe this project will lay the foundation for a new Silicon Heartland; a semiconductor ecosystem centered in the Midwest Triangle.
  • The IEDC also committed up to $45 million through the Industrial Development Grant Fund to support infrastructure improvements surrounding the new plant.